Ribociclib: Difference between revisions

Revision as of 11:40, 30 October 2023 view source Alexander Berchansky (talk \| contribs) 29,726 edits No edit summary ← Older edit		Revision as of 11:45, 30 October 2023 view source Alexander Berchansky (talk \| contribs) 29,726 edits No edit summary Newer edit →
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1004490/Cv/1'>
	Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib inhibits the enzymes [[Cyclin Dependent Kinase-4\|cyclin-dependent kinase 4]] (CDK4) and cyclin-dependent kinase 6 (CDK6).		Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib inhibits the enzymes [[Cyclin Dependent Kinase-4\|cyclin-dependent kinase 4]] (CDK4) and cyclin-dependent kinase 6 (CDK6).

Navigation menu